Predictive index of lung cancer immunotherapy curative effect and application thereof
By detecting specific oral flora and metabolites in saliva, predicting the response of lung cancer patients to immunotherapy, solving the problem of difficult prediction of ICI treatment response in the prior art, confirming the resistance of specific flora and fat metabolism in immunotherapy The role of the lung cancer immunotherapy is provided by new predictors.
Patent Information
- Application Number
- CN202411305792.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-19
AI Technical Summary
The prior art is difficult to effectively predict the response of lung cancer patients to immune checkpoint inhibitors (ICI) treatment, with approximately 70% of patients with advanced non-small cell lung cancer (NSCLC) failing to obtain lasting benefits from ICI treatment, and specific oral microbiota Distribution characteristics and mechanism are unclear.
The distribution of specific oral bacterial flora and metabolites in saliva were detected by Metagenomic Next-Generation Sequencing (mNGS) and non-targeted metabolomics liquid chromatography mass spectrometry analysis, and the distribution of specific oral bacteria in saliva were determined. Neisseria subflava, Neisseria perflava, Neisseria flavescens, Neisseria menuingitidis, Neisseria lactamica , Neisseria cinerea, Actinomyces meyeri, Actinomyces hongkongensis, Actinomyces georgiae, Granulicateella adiacens and Streptococcus oralis, to predict the efficacy of lung cancer immunotherapy and verify its relationship with fat metabolism.
Successfully predicted the response and non-response of lung cancer immunotherapy, confirmed that specific oral flora and fat metabolism play an important regulatory role in immunotherapy resistance, and verified its impact on PD-L1 expression, providing lung cancer immune regulation New evidence of factors.
Smart Images

Figure CN118995934A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of predictive markers, and in particular to a predictive index for the efficacy of lung cancer immunotherapy and an application thereof. Background Art
[0002] Lung cancer remains a significant public health problem. It is estimated that by 2024, nearly 125,070 people in the United States will die from lung cancer. Over the past decade, significant advances have been made in the treatment of lung cancer. A deeper understanding of the biology of lung cancer has led to the development of targeted therapies and immunotherapies. Immune checkpoint inhibitors (ICIs) have shown significant benefits in the treatment of non-small cell lung cancer (NSCLC) and are now considered first-line treatments for advanced lung cancer. However, despite the significant progress of ICIs in the treatment of NSCLC, it is clear that a significant number of patients do not respond well to these treatments. Nearly 70% of patients with advanced NSCLC fail to achieve durable benefit from ICI-based therapy.
[0003] Therefore, it is crucial to investigate the mechanisms of immunotherapy resistance and to find potential predictive markers. The barrier surface of the human body is home to a complex bacterial community. The functions encoded within the human microbiome play an important role in various aspects of human physiology. The oral microbiome is the second most diverse habitat in the human body after the gut microbiome. The oral microbiota interacts with its host's immune system and plays a role not only in oral health but also in systemic health, including lung disease. It is reasonable that the oral microbiome is associated with the efficacy of immunotherapy in patients with lung cancer. However, the specific distribution characteristics and mechanisms of the oral microbiome in immunotherapy-sensitive and immunotherapy-resistant lung cancer patients remain unclear. Summary of the invention
[0004] The purpose of the present invention is to provide a predictive index for the efficacy of lung cancer immunotherapy and its application to solve the problems existing in the above-mentioned prior art. The present invention discloses the important regulatory role of specific oral flora distribution on immunotherapy resistance, and confirms that its related fat metabolism is highly enriched in lung cancer patients with immunotherapy resistance.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] Technical Solution 1: A predictive indicator for the efficacy of immunotherapy for lung cancer, the predictive indicator comprising a specific oral flora; the specific oral flora comprising Neisseria subflava, Neisseria perflava, Neisseriaflavescens, Neisseria meningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis, Actinomyces georgiae, Granulicatella adiacens and Streptococcus oralis.
[0007] Furthermore, the sample of the prediction indicator is saliva.
[0008] Technical solution 2: Application of the quantitative detection reagent of the prediction index in the preparation of a lung cancer prognosis prediction reagent.
[0009] Furthermore, the efficacy of lung cancer immunotherapy is predicted by detecting the distribution concentration of the specific oral flora.
[0010] Furthermore, the Youden index of the ROC curve was used as the critical value, and the lung cancer patients with a test score ≥ Youden index were defined as a high concentration group, and the lung cancer patients with a test score < Youden index were defined as a low concentration group; when the specific oral flora Neisseria subflava, Neisseria perflava, Neisseria flavescens, Neisseriameningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis and Actinomyces georgia were distributed in high concentrations, it was a response to lung cancer immunotherapy; when the specific oral flora Granulicatella adiacens and Streptococcus oralis were distributed in high concentrations, it was a non-response to lung cancer immunotherapy.
[0011] The present invention discloses the following technical effects:
[0012] The present invention analyzes saliva microbiome and metabolite data based on non-targeted metabolomics liquid chromatography mass spectrometry (LC / MS) of Metagenomic Next-Generation Sequencing (mNGS). Through multi-omics analysis, it is found that the distribution of specific oral flora has an important regulatory effect on immunotherapy resistance, and confirms that its related fat metabolism is highly enriched in lung cancer patients with immunotherapy resistance. When the specific oral flora Neisseria subflava, Neisseria perflava, Neisseria flavescens, Neisseria meningitidis, Neisseria lactamica, Neisseriacinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis and Actinomyces georgia are distributed in high concentrations, it is a response to lung cancer immunotherapy; when the specific oral flora Granulicatella adiacens and Streptococcus oralis are distributed in high concentrations, it is a non-response to lung cancer immunotherapy. In addition, through in vitro experiments, the present invention further confirmed that lung cancer immunotherapy resistance is closely related to abnormal fat metabolism and verified its effect on the expression of the checkpoint PD-L1. Therefore, the present invention confirms and emphasizes the value of specific oral flora as an immunomodulatory factor for lung cancer and determines its related lipid metabolism in regulating immune signaling pathways. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0014] Figure 1 The saliva microbial community composition of lung cancer patients is shown in Figure 1, where A is the main phylum composition in lung cancer patients; B is the main genus distribution in lung cancer patients; C is the distribution of the top 20 oral bacterial species in lung cancer patients;
[0015] Figure 2 The salivary flora structure between the NR and R groups, among which (AD)α diversity analysis showed that ACE(A), Chao1(B), There were no significant differences in the Shannon index (D) and the Bray-Curtis distance-based PCOA (E) and the Jaccard distance (F) between the two groups, as shown in (EF) β diversity analysis.
[0016] Figure 3 Figure 3 shows the differential bacterial species between NR and R patients, among which 13 differential species were identified by LEfSe analysis in A; among them, 11 species were more enriched in the R group and 2 species were more enriched in the NR group; N: responder; NR: non-responder; Distribution and abundance of 12 major differential bacterial species identified by LEfSe in B; P value was calculated by Mann-Whitney U test; *p<0.05, **p<0.01; N: responder; NR: non-responder; C-F shows Kaplan-Meier analysis of lung cancer patients according to the median abundance of each dominant differential species; The high-level Neisseria subflava C and Actinomyces meyeri D groups had a significant survival advantage over the low-level groups; The low-level Granulicatella adiacens (E) and Streptococcusoralis (F) groups had a significant survival advantage over the high-level groups; P value was calculated by Log-rank test; *p<0.05;
[0017] Figure 4 To investigate the changes in the main 12 differential bacterial species identified by Lefse between NR and NR-PD patients, saliva samples of NR patients at the time of disease progression were collected and classified as NR-PD, and the results showed that these 12 differential species remained stable during lung cancer treatment;
[0018] Figure 5 Figure 2 is the relationship between saliva microbiome and PD-L1 expression, where A is the identification of several differential bacterial species by LEfSe analysis in patients with PD-L1 ≥ 10%; BE is the Spearman correlation analysis between the main differential bacterial species and PD-L1 expression; Neisseria subflava (B) and Actinomyces meyeri (C) were positively correlated with PD-L1 expression; Granulicatella adiacens (D) and Streptococcus oralis (E) were not significantly correlated with PD-L1 expression;
[0019] Figure 6Metabolomics analysis revealed unique metabolic profiles between the NR and R groups; PLS-DA analysis of the AB positive ion model (A) and the negative ion model (B) showed that the metabolic patterns between the two groups were significantly different; the differential metabolites of the CD positive ion model (C) and the negative ion model (D) were shown in the circular volcano plot, most of which were lipids and lipid-like molecules;
[0020] Figure 7 Figure 2 is a hierarchical clustering heat map showing the differential metabolite abundance of each patient; data were normalized based on Z-scores; A is a positive ion model; results show that most differential metabolites were enriched in NR patients; all lipids and lipid-like molecules were enriched in the NR group and clustered together; B is a negative ion model; results show that most differential lipids and lipid-like molecules were enriched in the NR group and clustered together;
[0021] Figure 8 The sum of all lipids and lipid-like molecules in the negative ion model A and the positive ion model B was significantly associated with PD-L1 expression; P values and r values were calculated by Spearman analysis;
[0022] Fig. 9 Correlation heatmaps of differential metabolites and differential species in the two groups were performed with Spearman correlation analysis, and the color intensity represents the r value; A is a positive ion model, and several differential metabolites including lipids and lipid-like metabolites are significantly correlated with certain bacterial species; B is a negative ion model;
[0023] Fig.10 ROC curve results were used to analyze the predictive sensitivity and specificity of Neisseria subflava, Neisseriaperflava, Neisseriaflavescens, Neisseria meningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis, Actinomyces georgiae and Lactobacillus fermentum, Granulicatella adiacens and Streptococcus oralis flora for the immunotherapy of patients with lung cancer. DETAILED DESCRIPTION
[0024] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0025] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0026] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0027] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0028] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0029] Example 1
[0030] 1. Experimental Methods
[0031] 1. Patient recruitment: From July 2021 to September 2022, 20 newly diagnosed stage IIIB-IV NSCLC patients were recruited in the Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, China.
[0032] 2. The inclusion criteria are as follows: (1) The diagnosis of advanced non-small cell lung cancer was confirmed by histopathological biopsy and imaging; (2) No anti-tumor treatment was received before sampling, including surgical treatment, chemotherapy, radiotherapy, targeted therapy, immunotherapy, traditional Chinese medicine treatment, etc.; (3) Age between 18 and 79 years old; (4) PS score was 0-1; (4) No antibiotic treatment was received within 1 month before sampling.
[0033] 3. Exclusion criteria are as follows: (1) patients with a history of primary malignant tumors of other systems; (2) patients with acute oral infection, acute lung infection, acute exacerbation of chronic obstructive pulmonary disease, bronchial asthma, infectious bronchiectasis, active pulmonary tuberculosis and other acute infectious diseases in the past 4 weeks; or patients with severe heart, respiratory, kidney, or liver dysfunction; (4) patients who have used oral hormones, immunosuppressants or microbial preparations in the past 4 weeks; (5) patients with irregular anti-tumor treatment cycles; (6) patients with lung adenocarcinoma with EGFR, ALK, ROS1, BRAF V600, NTRK, or MET exon 14 mutations. All enrolled patients received immunotherapy combined with chemotherapy as first-line treatment.
[0034] 4. Tumor efficacy evaluation was evaluated using the immune-modified solid tumor response evaluation criteria (ImRECIST). The treatment response was evaluated every 2 treatment cycles. When iUPD occurs, it must be confirmed by a follow-up evaluation at least 4 weeks after the first recording date. Patients in the present invention are defined as responders (R) (sustained complete remission, partial remission or stable disease for more than 9 months after the first cycle of treatment) or non-responders (NR) (disease progression within 9 months of the first cycle of treatment).
[0035] 5. Sample collection and storage: All study subjects were instructed to brush their teeth thoroughly and then refrain from eating or taking any oral hygiene measures before collecting saliva samples the next morning. Saliva samples were collected from each participant before brushing their teeth in the morning and placed in a 20 ml disposable sterile sample cup before treatment. Approximately 5 ml of saliva was collected from each person. The saliva did not contain impurities such as blood, food residues, sputum, etc. Otherwise, resampling was required. Saliva samples were collected before the first cycle of anti-tumor treatment. For patients in the NR group, saliva samples were collected again when the tumor treatment effect assessment indicated disease progression (PD). The samples were stored in a -80°C refrigerator until further processing.
[0036] 6. Nucleic acid extraction and sequencing: DNA was extracted from all samples using the TIANamp bacterial DNA kit (DP302-02, Beijing TIANGEN) and followed the manufacturer's instructions. DNA concentration was calibrated using Qubit reagent (Q33230, Thermo Fisher Scientific, Invitrogen, Carlsbad, CA, USA). The Fragmentation Mix (FRM) reaction solution (SQK-RPB004 Rapid PCR barcode kit (Nanopore), Oxford Nanopore Technologies, Oxford, UK) was prepared in a 0.2 mL PCR tube, gently stirred, mixed evenly, incubated at 30 ° C for 5 min, incubated at 80 ° C for 1 min, and then quickly cooled on ice. After the PCR product was transferred to a 1.5 mL centrifuge tube, an equal amount of 50 μL purified magnetic beads was added, mixed evenly, left to stand at room temperature for 5 min, and then centrifuged immediately. When the solution becomes clear, the supernatant is discarded. Wash twice with 180 μL 80% ethanol, centrifuge the sample immediately at 3000 rpm for 1 min, place it on a magnetic rack to absorb the residual ethanol, open the lid and dry it for 30 seconds at room temperature, add 10 μL of 10 mM Tris-HCl (pH = 8.0, PHG0002, SAFC Biosciences, Lenexa, KS, USA) and 50 mM NaCl (S8210, Solarbio Life sciences, Beijing, China) mixed solution, and gently rotate the suspended magnetic beads. After incubation at room temperature for 2 min, place the sample on a magnetic rack. When the solution becomes clear, draw the eluent for subsequent use. The concentration of each sample eluent is calibrated using Qubit reagent. According to the relevant concentration, the same absolute amount of template was used, mixed into 10 μL, with a total concentration range of 100 to 200 ng / μL, 1 μL of PipedAdapter (RAP) solution (SQK-RPB004 Rapid PCR barcoding kit (Nanopore), Oxford Nanopore Technologies, Oxford, UK) was added, mixed gently, and incubated at room temperature for 15 min. When the loading mixture was ready within 15 min, sequencing was performed. The amount of sequencing data was 500 Mb.
[0037] 7.Nanopore sequencing and microbial data analysis: Raw data files were generated in fast5 format using MinION sequencer (Oxford Nanopore Technologies, Oxford, UK), and real-time identification and fastq file generation were completed using MinKnow software (version 1.11.5, Oxford Nanopore Technologies, Oxford, UK). Low-quality sequences were filtered using MinKnow software. Host DNA in the filtered data was removed using Minimap2 software (version 2.17.r941, Broad Institute, Cambridge, MA, USA) and human genome reference sequence Hg38. Multiple sequence alignment and identification of pathogenic microorganisms were performed using Centrifuge v1.0.3 (http: / / www.ccb.jhu.edu / software / centrifuge / , Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA) and NCBI's non-redundant nucleic acid database for filtered sequences. Species counts and relative abundance tables were entered into R-base V.4.1.0 for statistical analysis. For alpha diversity, the present invention selected the ACE index, Chao index, and Simpson and Shannon index for evaluation. For beta diversity analysis, the present invention used Bray-curits distance and Jaccard distance, and visualized by principal coordinate analysis (PCoA). Differential classification was identified by linear discriminant analysis effect size (LEfSe) analysis in http: / / huttenhower.sph.harvard.edu / galaxy.
[0038] 8.LC / MS analysis: UHPLC-MS / MS analysis was performed using a Vanquish UHPLC system (ThermoFisher, Germany) with an OrbitrapQExactive TMHF mass spectrometer (Thermo Fisher, Germany). The sample was injected onto a HypesilGold column (100×2.1 mm, 1.9 μm) using a 17 min linear gradient at a flow rate of 0.2 mL / min. Solvent A in the positive polarity mode was 0.1% FA in water, and solvent B was methanol. Solvent A in the negative polarity mode was 5 mM aminoacetic acid at pH 9.0, and solvent B was methanol. The solvent gradient was set as follows: 2% B, 1.5 min; 2-85% B, 3 min; 85-100% B, 10 min; 100-2% B, 10.1 min; 2% B, 12 min. The Q ExactiveTM HF mass spectrometer was operated in positive / negative polarity mode with a spray voltage of 3.5 kV, a capillary temperature of 320 °C, a sheath gas flow rate of 35 psi, an auxiliary gas flow rate of 10 L / min, an S-lens RF level of 60, and an auxiliary gas heater temperature of 350 °C.
[0039] 9. Data processing and metabolite identification: The raw data files generated by UHPLC-MS / MS were processed using Compound Discoverer 3.1 (CD3.1, ThermoFisher) to perform peak alignment, peak selection, and quantification for each metabolite. The main parameters were set as follows: retention time tolerance, 0.2 min; actual mass tolerance, 5 ppm; signal intensity tolerance, 30%; signal / noise ratio, 3; and minimum intensity, etc. Afterwards, the peak intensity was normalized to the total spectral intensity. The normalized data was used to predict the molecular formula based on the added ions, molecular ion peaks, and fragment ions. The peaks were then matched with the mzCloud (https: / / www.mzcloud.org), mzVault, and MassList databases to obtain accurate characteristics and relative quantitative results. Statistical analysis was performed using statistical software R (R version R-3.4.3), Python (Python 2.7.6 version), and CentOS (CentOS release 6.6).
[0040] 10. Metabolite data analysis: These metabolites were annotated using the HMDB database and the LIPIDMaps database. Orthogonal partial least squares discriminant analysis (OPLS-DA) was performed using the OmicStudio tool (https: / / www.omicstudio.cn / tool). The present invention applies the Mann-Whitney U test to calculate statistical significance (p-value). Partial least squares discriminant analysis (PLS-DA) was performed to calculate VIP scores. Metabolites with VIP>1 and p-value<0.05 and a change factor ≥1.5 or ≤0.67 were considered differential metabolites. For cluster heat maps, the data were normalized using the intensity area z-scores of the differential metabolites and performed on https: / / www.omicstudio.cn / tool.
[0041] 11. Statistical analysis: Independent sample continuous variables were compared by Mann-Whitney U test or independent t test. Wilcoxon signed-rank test was used for paired sample test. Categorical variables were compared by Fisher's exact test. p value < 0.05 was considered statistically significant. Spearman analysis was used to explore the correlation between different classifications, as well as the correlation between classifications and metabolites.
[0042] 2. Results
[0043] 1. Patient characteristics: A total of 20 newly diagnosed stage III B-IV NSCLC patients participated in the study. The basic information and clinical characteristics of these patients are listed in Table 1. All patients were followed up until disease progression or death, and the last follow-up was conducted on January 3, 2023.
[0044] Table 1 Basic information and clinical characteristics of patients
[0045]
[0046]
[0047] Based on clinical evaluation, patients were divided into two groups, 10 patients were evaluated as R (immunotherapy responders), and the remaining 10 (n = 10) had disease progression within 9 months after the first cancer treatment cycle and were classified as NR (immunotherapy non-responders). The average age of the 20 NSCLC patients was approximately 60 years old, and most patients were male. No significant differences were observed between the patient groups in terms of age, BMI, gender, disease history, disease stage, smoking history, antibiotic use, PD-L1 expression, pathological type, and clinical stage.
[0048] 2. Bacterial composition and diversity between NR and R groups: Overall, 3433 pathogens were identified in the saliva samples of 20 patients through in-depth metagenomic sequencing. The sequence reads of each saliva sample were standardized to 1 million. The bacterial taxonomic composition of all participants was as follows Figure 1 The present invention illustrates the distribution characteristics of the microbiota of lung cancer patients receiving immunotherapy. At the phylum level, the most abundant phyla are Actinobacteria, Bacillus, and Bacteroidetes ( Figure 1 At the genus level, the top five genera are Rothia, Streptococcus, Prevotella, Porphyromonas, and Actinomyces ( Figure 1 B). At the species level, Rothia species, Streptococcus species, Actinomyces species, and Prevotella species were common ( Figure 1 C). Among them, the top 10 species were Rothia mucilaginosa, Streptococcusparasanguinis, Porphyromonas somerae, Prevotella melaninogenica, Streptococcussalivarius, Streptococcus mitis, Streptococcus_oralis, Neisseria_subflava, Actinomyces graevenitzii and Prevotellapallens. In order to compare the differences in bacterial diversity associated with immunotherapy sensitivity and resistance, the present invention compared the α and β diversity of the saliva microbiomes of the NR and R groups. At the species level, the ACE index ( Figure 2 A) and Chao1 index ( Figure 2 The Simpson index (B) was similar between the R and NR groups. Figure 2 C) and Shannon index ( Figure 2 The D) showed a trend of lower diversity in the R group, but the result did not reach statistical significance. For β-diversity analysis, the Bray-Curtis distance ( Figure 2 E) and Jaccard distance ( Figure 2 F) PCOA was performed at the species level to visualize the dissimilarity between the salivary taxonomic communities of the two groups. The results showed that the two groups shared common species with similar species abundance. There was no significant difference in oral bacterial diversity between immunotherapy responders and non-responders in NSCLC patients.
[0049] 3. Differential species associated with immunotherapy response: To further explore specific oral bacterial species associated with immunotherapy efficacy, LEfSe analysis was performed on the NR and R groups. A total of 11 R-enriched species and 2 NR-enriched species were found. Among them, Neisseria and Actinomyces species were common ( Figure 3 Specifically, the species that increased significantly in the R group were Neisseriasubflava, Neisseriaperflava, Neisseriaflavescens, Neisseriameningitidis, Neisserialacamica, Neisseriacinerea, Neisseriapolysaccharea, Actinomycesmeyeri, Actinomyceshongkongensis, Actinomycesgeorgiae, and Lactobacillusfermentum, while the species that increased significantly in the NR group were Granulicatellaadiacens and Streptococcusoralis( Figure 3 A). Except for Lactobacillus fermentum, the abundance of the other 12 differential species was ≥1000 and was used for further analysis. The distribution and abundance of these 12 differential species are shown in Figure 3 As shown in B. The Man-Whitney U test further revealed significant differences in species distribution between the two groups. In the R group, Neisseria subflava was the most abundant species in the genus Neisseria, while Actinomyces meyeri was the most abundant species in the genus Actinomyces. The two enriched species, Granulicatella adiacens and Streptococcus oralis, had the highest abundance in the NR group. These 12 differential species are listed in Table 2. The present invention shows that high concentrations of Neisseria and Actinomyces species are characteristics of responders to lung cancer immunotherapy. In contrast, high concentrations of Granulicatella adiacens and Streptococcus oralis are characteristics of non-responders to lung cancer immunotherapy.
[0050] Table 2 Twelve different bacterial species associated with immunotherapy response
[0051] Bacteria Average abundance (NR group) Average abundance (R group) LDA score P-value Neisseria_subflava 7562.64 30752.474 3.96 0.008a Neisseria_perflava 977.60 3889.804 3.06 0.013a Neisseria_flavescens 951.17 4023.372 3.10 0.016a Neisseria_meningitidis 261.72 928.441 2.42 0.023a Actinomyces_meyeri 1714.63 2620.344 2.79 0.028a Neisseria_lactamica 147.50 567.081 2.20 0.028a Neisseria_cinerea 306.61 1117.884 2.51 0.034a Neisseria_polysaccharea 139.36 527.855 2.16 0.041a Actinomyces_hongkongensis 818.49 2314.780 2.80 0.041a Actinomyces_georgiae 506.14 1162.273 2.48 0.049a Streptococcus_oralis 29954.22 14749.977 3.99 0.049a Granulicatella_adiacens 9481.12 4577.990 3.55 0.041a
[0052] Given the potential for variability in the abundance of salivary microbial communities over time, the goal of this study was to determine whether these 12 differential bacteria were stable during lung cancer immunotherapy. To this end, we collected saliva samples from all non-responding patients at the time of disease progression (PD) and performed mNGS sequencing. The results showed that the abundance of these 12 differential species remained stable ( Figure 4 ), indicating that it can be used as a predictor of immunotherapy efficacy. Spearman correlation analysis was performed to measure the relationship between these 12 differential species ( Figure 4 ), the results showed that there was a strong correlation between the seven Neisseria species, as well as between the three Actinomyces species. In addition, Granulicatella adiacens showed a moderate correlation with Streptococcus oralis.
[0053] The present invention uses the Youden index in the ROC curve as the optimal diagnostic critical value, that is, the cut-off value ( Fig.10 ), showing the high and low grouping of Neisseria subflava, Neisseria perflava, Neisseria flavescens, Neisseriameningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis, Actinomyces georgiae, Lactobacillus fermentum, Granulicatella adiacens and Streptococcus oralis. The area under the ROC curve (AUC) was used to evaluate the predictive sensitivity and specificity of the above 12 bacterial species indicators, such as Fig.10 As shown, it has good predictive ability for the immunotherapy effect on lung cancer patients. The present invention tested whether Neisseria subflava, Actinomyces meyeri, Granulicatella adiacens and Streptococcus oralis were associated with progression-free survival (PFS) of lung cancer immunotherapy. All patients were divided into two groups according to the median level of each species. Kaplan-Meier analysis showed that Neisseria subflava ( Figure 3 C) and Actinomyces meyeri ( Figure 3Patients with higher abundance of Granulicatella adiacens ( Figure 3 E) and Streptococcus oralis ( Figure 3 Patients with higher abundance of F) tend to have shorter PFS. This indicates that the distribution of specific bacteria is closely related to the patient's treatment outcome, further suggesting that the detection of specific bacteria can be used as a predictive indicator for immunotherapy.
[0054] 4. Differential species associated with PD-L1 expression: PD-L1 is an important therapeutic target and detection marker for immunotherapy. To further support the close connection between oral bacterial distribution and immunotherapy, the present invention analyzed the expression and distribution of PD-L1 and different major bacteria in N and NR groups of lung cancer. The patients were divided into two groups according to PD-L1 <10% and PD-L1 ≥10%. Interestingly, LEfSe analysis showed that most R-enriched species, including: Neisseria subflava, Neisseria perflava, Neisseria flavescens, Neisseria meningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis, and Actinomyces georgiae were also significantly increased in the PD-L1 high group ( Figure 5 A). Spearman correlation analysis showed that Neisseria subflava was strongly correlated with PD-L1 expression (P<0.001, R=0.925) ( Figure 5 B), while Actinomyces meyeri was moderately correlated with PD-L1 expression (P<0.05, R=0.571)( Figure 5 C), while Granulicatella adiacens( Figure 5 D) and Streptococcus oralis ( Figure 5E) had no significant correlation with PD-L1 expression. In the R group, Neisseria and Actinomyces species were significantly enriched and positively correlated with PD-L1 expression, indicating that these bacteria are associated with immunotherapy sensitivity. In contrast, Granulicatella adiacens and Streptococcus orali were significantly enriched in the NR group and associated with low PD-L1 expression, indicating that they are bacteria associated with lung cancer immunotherapy resistance. These results highlight the importance and significance of the differences in the distribution of specific oral bacteria in lung cancer immunotherapy.
[0055] 5. Analysis of differences in metabolic patterns between the NR and R groups: Nutrients act as chemical signals that regulate cell growth and metabolism. Overnutrition not only disrupts metabolic balance, but also leads to excessive nutritional signals, which in turn promotes abnormal cell metabolism and proliferation, contributing to the development of various diseases, including cancer. In order to study the metabolic patterns of people with different immunotherapy effects and to find metabolites associated with the microbiome, the present invention performed LC / MS analysis. A total of 1,008 positive ion mode metabolites and 507 negative ion mode metabolites were identified in saliva samples. Given the sensitivity and rapid changes of metabolomics to external factors, quality control (QC) samples are often used to ensure data reliability. Based on the relative quantitative values of metabolites in the two ion modes, the Pearson correlation coefficient between QC samples was calculated, R 2 Values greater than 0.9 indicate high data quality ( Figure 6 In the PLS-DA model, the metabolic profile of NR can be distinguished from that of R ( Figure 6 AB). The differential metabolites between the NR and R groups were determined based on specific criteria: VIP ≥ 1 for the first two principal components of the PLS-DA model; fold change ≥ 1.5 or ≤ 0.67; P value < 0.05. The differential metabolites between the NR and R groups are listed in the circular volcano plot ( Figure 6 CD). 84 potential biomarker metabolites were identified in the negative ion mode, while 40 potential biomarker metabolites were identified in the positive ion mode. In order to determine whether these differential metabolites are stable during lung cancer treatment, the present invention collected saliva samples from all NR patients at PD and performed LC / MS analysis. The Wilcoxon rank sum test was used to compare the differential metabolites at different treatment time points. Finally, 70 differential metabolites in the negative ion mode and 28 differential metabolites in the positive ion mode remained stable. These stable differential metabolites are listed in Table 3 and used for further analysis. In both the negative ion mode (26 / 70, 37%) and the positive ion mode (14 / 28, 50%), most of the differential metabolites were lipids and lipid-like molecules.
[0056] Table 3 Differential metabolites in cationic and anionic modes
[0057]
[0058]
[0059]
[0060] 6. Among the differential lipid and lipid-like metabolites, most (15 in negative ion mode and 14 in positive ion mode) were upregulated in the NR group. The abundance heat map of stable differential metabolites in the two ion modes showed ( Figure 7 AB). Most of the differential lipid and lipid-like metabolites were clustered together. Correlation analysis showed that the total abundance of all lipid and lipid-like metabolites was negatively correlated with PD-L1 expression ( Figure 8 )(negative ion mode P = 0.029, R = -0.534 and positive ion mode P = 0.018, R = -0.572). These results revealed that abnormal fat metabolism was highly enriched in the NR group and was closely associated with low PD-L1 expression. In summary, the present invention clarifies the metabolic characteristics of lung cancer patients receiving immunotherapy.
[0061] 7. Specific correlation between different salivary microbial community species and different fat metabolites: In order to further reveal the specific correlation between differential bacteria and differential metabolites, the present invention performed Spearman correlation analysis ( Fig. 9 AB). Several differential lipids and lipid-like metabolites were associated with differential bacteria. In the positive ion mode, most of the differential phosphocholines and acylcarnitines were negatively correlated with differential Actinomycetes species. Most of the phosphocholine metabolites were positively correlated with Granulicatella adiacens or Streptococcus oralis. PC (14:0e / 26:2) and glycoursodeoxycholic acid were negatively correlated with differential Neisseria species. In the negative ion mode, most of the lipids and lipid-like metabolites enriched in the NR group were positively correlated with Granulicatella adiacens. All differential monoacylglycerol phosphatidylinositols were negatively correlated with differential Actinomycetes species. LPS20:2, myristic acid, SM (d14:0 / 22:0), and tetraene prostaglandin E2 were negatively correlated with differential Neisseria species, while most of the lipids and lipid-like metabolites enriched in the R group were positively correlated with differential Neisseria species ( Fig. 9 In conclusion, certain lipid and lipid-like metabolites enriched in the NR group were closely associated with specific salivary species that were associated with immunotherapy efficacy. This suggests that the specific oral microbial community profile associated with lung cancer immunotherapy is closely related to the dysregulation of lipid metabolic signaling.
[0062] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A predictive indicator for the efficacy of immunotherapy for lung cancer, characterized in that: The predictive indicators include specific oral flora; the specific oral flora include Neisseria subflava, Neisseria perflava, Neisseriaflavescens, Neisseria meningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis, Actinomyces georgiae, Granulicatella adiacens and Streptococcus oralis.
2. The prediction indicator according to claim 1, characterized in that The sample of the predictive indicator is saliva.
3. Use of the quantitative detection reagent for prediction indexes according to claim 1 in the preparation of a reagent for predicting the prognosis of lung cancer.
4. The use according to claim 3, characterized in that: The efficacy of lung cancer immunotherapy is predicted by detecting the distribution concentration of the specific oral flora.
5. The use according to claim 4, characterized in that: The Youden index of the ROC curve was used as the critical value, and the lung cancer patients with a test score ≥ Youden index were defined as a high concentration group, and the lung cancer patients with a test score < Youden index were defined as a low concentration group; when the specific oral flora Neisseria subflava, Neisseria perflava, Neisseriaflavescens, Neisseria meningitidis, Neisseria lactamica, Neisseria cinerea, Neisseria polysaccharea, Actinomyces meyeri, Actinomyces hongkongensis and Actinomyces georgia were distributed in high concentrations, it was a response to lung cancer immunotherapy; when the specific oral flora Granulicatella adiacens and Streptococcus oralis were distributed in high concentrations, it was a non-response to lung cancer immunotherapy.
Citation Information
Patent Citations
Construction method of prediction model for occurrence of immune-related adverse reaction event, marker and kit
CN116504409A
Methods of diagnosing cancer and predicting responsiveness to therapy
US20230203594A1
A predictive score of cancer immunotherapy outcome based on ecological analysis of gut microbiota
WO2024094817A1
Cited By
Anti-tumor preparation based on respiratory tract symbiotic bacteria as well as preparation method and application of anti-tumor preparation
CN121550264A
